Blog Archive

Saturday, March 26, 2022

RMO


 

Romeo Power and Wrightspeed Announce "Powertrain in a Crate(TM)" to Safely Repower School Buses, Transit Buses and Certain Medium and Heavy Duty Trucks Into Zero Emission Electric Vehicles

8:55 am ET March 11, 2022 (BusinessWire) Print

Romeo Power and Wrightspeed, today announced that they are working together to leverage Romeo Power's high-capacity battery packing and module technology along with Wrightspeed's high torque, high-efficiency powertrain system to accelerate electrification in the bus, and medium and heavy duty truck market.

There are over one million existing buses and trucks that are candidates for repowering to zero emission full battery electric right now, and at a much lower upfront cost than purchasing expensive new battery electric vehicles. Wrightspeed is developing "Powertrain in a Crate(TM)" kits that are chassis-specific and can be installed locally where fleets operate, creating jobs and new technology opportunities for those supporting school bus, work truck and other fleets. By using Wrightspeed's Route(TM) traction drive technology, the repowered vehicles will be more efficient and provide higher torque than new vehicles based on single speed remote mount systems.

Together, the companies intend to develop and sell repower kits to the addressable market. "Romeo Power's advanced electrification solutions for complex commercial vehicle applications is a perfect fit for our Route(TM) powertrain system. We are particularly impressed by their high level of safety, packaging density, and modularity," said Alan Dowdell, Acting CEO of Wrightspeed. "We are proud to team up with Romeo Power and set a new standard in performance and efficiency for electric buses and trucks."

Romeo Power and Wrightspeed together bring a unique combination of real-world, on-road experience and powertrain technology to accelerate electrification safely. After vehicles are selected and inspected, they will be rapidly decontented of the diesel or gas powertrains. The bespoke powertrain kits including traction drive axle with motors, inverters, battery modules and new dash with telematics will then be added to the vehicle. After thorough testing, the vehicle will be qualified to re-enter the fleet as a safe, quiet, efficient zero-emission bus or truck.

"Wrightspeed's medium and heavy-duty "Powertrain in a Crate(TM)" kits are a great way for our battery technology to help quickly and locally convert legacy diesel and gas vehicles to zero-emission electric vehicles" said Susan Brennan, Romeo's Chief Executive Officer. "We are as excited about Wrightspeed's technology and business model as we are about our new partnership."

The battery packs will be manufactured at Romeo Power's new state of the art facility in Cypress, California, where production is scheduled to begin later in 2022. The balance of the "Powertrain in a Crate" solution will be assembled in Wrightspeed's 110,000 square foot Alameda, California facility. The complete system will be shipped and installed near fleets locally with training and support from both Romeo Power and Wrightspeed.

About Romeo Power, Inc.

Founded in 2016 and headquartered in Los Angeles, California, Romeo Power (NYSE: RMO) is an energy technology leader delivering advanced electrification solutions for complex commercial vehicle applications. The Company's suite of advanced battery electric products, combined with its innovative battery management system, delivers the safety, performance, reliability and configurability its customers need to succeed. To keep up with everything Romeo Power, please follow the Company on social media @romeopowerinc or visit www.romeopower.com.

About Wrightspeed Inc.

Wrightspeed designs and manufactures the world's cleanest and most efficient electric vehicle (EV) powertrain for medium and heavy-duty vehicles. The company is revolutionizing the environmental impact and economics of heavy transportation by delivering world class EV technology where it's needed most. Founded in 2005, Wrightspeed is headquartered and manufactures in Alameda, California. For more information about Wrightspeed, visit wrightspeed.com or send an email to contact@wrightspeed.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220311005133/en/

SOURCE: Romeo Power

For Investors: 
Joe Caminiti or Ashley Gruenberg
Alpha IR Group
RMO@alpha-ir.com 
312-445-2870
comtex tracking

COMTEX_403949698/1006/2022-03-11T08:55:00

NXPL

 

Market cap
24.91M
Price-Earnings ratio
Dividend yield
Average volume
40.23K
High today
$2.79
Low today
$2.66
Open price
$2.79
Volume
30.49K
52 Week high
$14.85
52 Week low
$2.38

GALT

 Your market value APRIL 4/5/2024
$3.80
Today‘s return        +$0.50 (+15.00%)
Total return        +$1.21 (+46.99%)
Your average cost
$2.35
Shares        1.1
Portfolio diversity        0.12%

 8:00 am ET January 6, 2022 (Globe Newswire)

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. Mr. Joel Lewis, President and Chief Executive Officer, and Dr. Pol F. Boudes, Chief Medical Officer, will be presenting on behalf of the Company.

A webcast of this presentation will be available on the "Investor Relations" section under "Events and Presentations" of the Company's website, https://investor.galectintherapeutics.com, at 7:00 a.m. ET on January 10, 2022. A replay will be accessible on Galectin's website for 90 days following the event.

About Galectin Therapeutics

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. 

Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. 

The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. 

This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. 

Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Company Contact:

Jack Callicutt, Chief Financial Officer

(678) 620-3186

ir@galectintherapeutics.com

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor GR-MD-02.

https://ml.globenewswire.com/media/dd593f5d-61a4-4e6b-87d3-b9deb9f5d33f/small/galectin-jpg.jpg

https://ml.globenewswire.com/media/dd593f5d-61a4-4e6b-87d3-b9deb9f5d33f/small/galectin-jpg.jpg

comtex tracking

COMTEX_400129051/2010/2022-01-06T08:00:01

EOSE day trade study

EOSE  sold on 09/30/2024 gained 101.03  buy back 2.68 20 share on 10/01/2024 gained= 5 $   

Labels